Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edgewise Therapeutics (EWTX) Cash & Equivalents (2020 - 2026)

Edgewise Therapeutics has reported Cash & Equivalents over the past 7 years, most recently at $499.6 million for Q1 2026.

  • Quarterly results put Cash & Equivalents at $499.6 million for Q1 2026, up 14.48% from a year ago — trailing twelve months through Mar 2026 was $499.6 million (up 14.48% YoY), and the annual figure for FY2025 was $61.1 million, up 46.76%.
  • Cash & Equivalents reached $499.6 million in Q1 2026 per EWTX's latest filing, up from $61.1 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $594.0 million in Q2 2025 and bottomed at $22.0 million in Q4 2022.
  • Median Cash & Equivalents over the past 5 years was $248.4 million (2022), compared with a mean of $229.7 million.
  • The largest annual shift saw Cash & Equivalents plummeted 90.77% in 2024 before it skyrocketed 1341.98% in 2025.
  • Over 5 years, Cash & Equivalents stood at $22.0 million in 2022, then surged by 291.47% to $86.1 million in 2023, then tumbled by 51.61% to $41.7 million in 2024, then soared by 46.76% to $61.1 million in 2025, then skyrocketed by 717.03% to $499.6 million in 2026.
  • Business Quant data shows Cash & Equivalents for EWTX at $499.6 million in Q1 2026, $61.1 million in Q4 2025, and $46.0 million in Q3 2025.